Who can enter
- Children with advanced skin cancer (melanoma), solid tumor or lymphoma in whom the disease has recurred (relapse)
- Age: 6 months to 17 years
Goal
In this study, we will evaluate how safe the study drug MK-3475 (pembrolizumab) is for the treatment of melanoma, solid tumors or lymphoma in children from 6 months to 17 years of age. We will also observe whether the study drug is well tolerated and how it works.
Also, we measure what happens to the study drug in the body, and determine how treatment with the study drug helps fight the disease.
Background
More research is needed on cancer treatment for children and adolescents. Often there are not many drugs available yet, or the drugs are only approved for adults.
This study uses MK-3475 (pembrolizumab) as a potential treatment for melanoma, solid tumors and lymphoma in children between the ages of 6 months and 17 years. Pembrolizumab, also known as KEYTRUDA®, can be given by doctors for several types of cancer but not yet to children for the types of cancer studied here. It is therefore called a study drug in this study.
Pembrolizumab is an immunotherapy that helps the immune system fight cancer cells. Pembrolizumab has already been approved for many different types of cancer and also for certain types of cancer in children. But not yet for all types of cancer, and not yet for children of all ages. Therefore, in this study, pembrolizumab is given to children and adolescents with different types of cancer.